Why Your Regulatory Writers Need eCTD Authoring Templates
If you’ve heard about eCTD authoring template suites before, but you’re not sure what they…
Certara2021 年 5 月 14 日
Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate
As model‐informed drug development becomes an integral part of modern approaches to the discovery of…
Certara2021 年 5 月 13 日
Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics
Perhaps the most important lesson learned from the COVID‐19 pandemic is that of preparedness. Enhanced…
Certara2021 年 5 月 11 日
Early Engagement with HTA Bodies
In-depth guide to successful early HTA engagement.
Certara2021 年 5 月 10 日
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Watch this presentation to learn • Overview of the SNDS and the key working practices…
Certara2021 年 5 月 7 日
Maximizing Oligonucleotide Therapeutic Development: How They Work
This is the first of three blog posts discussing best practices for developing oligonucleotides. Interest…
Certara2021 年 5 月 7 日
The Wizard of Oligos: There’s no place like having a successful drug development program!
Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…
Certara2021 年 4 月 30 日
The Promises and Pitfalls of Gene Therapy for Rare Diseases
The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…
Certara2021 年 4 月 29 日
Regulatory Writing
Expert Writing. Faster Approvals. Read our Regulatory Writing Factsheet
Certara2021 年 4 月 28 日
